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Summary We report a comparative study of CA 15.3 and EMCA (epithelial mucin core antigen) in 77
consecutive women with newly diagnosed UICC assessable metastatic breast cancer; 59 patients received
hormones and 18 chemotherapy. Assessments of response were made prior to commencing therapy and
repeated 2 monthly. Sites of metastatic disease included bone (34), pulmonary (8), bone and pulmonary (14)
and visceral (21). Using a cut-off of 33 U ml-' changes in EMCA at 2, 4 and 6 months showed a highly
significant correlation (P<0.001) with UICC assessed response at 6 months; selectivity 70%, sensitivity 80%,
specificity 91%, positive predictive value 84%; negative predictive value 89% at 2 months. Corresponding
values for CA 15.3: selectivity 89%, sensitivity 85%, specificity 91%, PPV 92% and NPV 91%. Four of eight
patients unassessable by CA 15.3 were assessable by EMCA; four patients expressed neither marker.
EMCA appears to reflect tumour bulk and may be useful in monitoring therapy in patients with advanced
breast cancer. With an easier and more robust assay format than CA 15.3, EMCA is potentially a more useful
marker.
High-molecular weight glycoproteins, often described as
mucins or mucin-like glycoproteins are associated with breast
cancer. These highly immunogenic molecules have been
identified as target antibodies for many monoclonal anti-
bodies raised against breast carcinoma cells (e.g., CA 15.3) or
human milk fat globule membranes (Price et al., 1985); they
also react with normal tissue, particularly luminal surfaces of
glandular epithelia (Ellis et al., 1984). Their relevance to
clinical studies in breast cancer is that they are detectable in
the serum of patients with metastatic disease. Early reports
indicated that CA 15.3 levels were raised in patients with
breast cancer compared to controls (Hayes et al., 1986; Pons-
Anicet et al., 1987), that the percentage of breast cancer
patients with elevated levels increases with stage of disease
(Kerin et al., 1989) and that CA 15.3 might be useful for
monitoring response to therapy (Sacks et al., 1987; Tondini
et al., 1988).
EMCA (epithelial membrane core antigen) monoclonal
antibody, also known as C595 and NCRC-48, arose out of
an investigation to produce a 'second generation' IgG mono-
clonal antibody against mucin antigens bearing the NCRC-
11 defined epitope (Price et al., 1990). The antibody C595
(IgG3) was prepared using the spleen cells of a mouse
immunised with purified polymorphic epithelial mucin. Puri-
fied PEM preparations were isolated by immunoadsorbent
chromatography from breast carcinoma cells, ascitic fluid
and from the urine of normal individuals.
The present study was initiated to determine whether
sequential measurement of EMCA in patients undergoing
therapy for metastatic breast cancer correlated with the
clinical course of the disease and undertake a comparison
with CA 15.3.
Materials and methods
Patients and serum samples
Sequential serum samples were obtained from 77 consecutive
women with newly diagnosed and UICC (Hayward et al.,
1977) assessable systemic breast cancer. The mean age ± s.d.
of the group was 57.9 ± 11.4 years; 59 patients received
primary hormonal therapy and 18 cytotoxic chemotherapy.
The principle sites of metastatic disease included bone
(n = 34), pulmonary (n = 8), bone and pulmonary (n = 14)
and visceral (n = 21). Samples were stored in small aliquots
of -20C. Upon completion of collection of all sera, these
were analysed for EMCA and CA 15.3 defined PEM antigen,
samples from each patient being assayed within a single
assay.
Patients were assessed for response to therapy by UICC
criteria as having responsive i.e., complete (CR) or partial
(PR), static (SD) or progressive (PD) disease. Assessments
were made prior to commencing therapy and repeated at 6-8
and 12-16 weeks and again at 6 months. As recommended
by the British Breast Group, response and static disease
reported within this study were for a minimum period of 6
months (British Breast Group, 1974). Patients assessed as
having either responsive or static disease for a minimum
duration of >6 months were then combined into a larger
non-progression group and compared to those patients
whose disease progressed within 6 months.
EMCA (NCRC-48) serum antigen assay
The Milenia assay for circulating PEM, as defined by the
EMCA antibody is a microtitre plate based immunoassay
(DPC-ERI, Witney, Oxford, UK). Sample, standard or con-
trol serum (25ftl) were incubated for 30 min in ligand coated
wells together with 100 LIl ligand coated EMCA antibody
solution and 100pl horseradish peroxidase-labelled EMCA
antibody solution. During a second 30min incubation the
addition of a multi-valent anti-ligand created a bridge
between ligand labelled EMCA antibody and the wall of the
plate. The microplate was washed to remove unreacted
material and 200 il substrate solution (hydrogen peroxide
with o-phenylenediamine as chromogen) was added. The
plate was transferred immediately to a kinetic plate reader
and the rate ofcolour development at 450 nm was monitored
in each of 96 wells over 5 min. Rate of change of absorbance
(mOD/min) for the calibrators was transformed into a cali-
bration curve by means of a 4-parameter curve fit. The rate
of colour development was proportional to EMCA concen-
tration.
CA 15.3 serum antigen assay
CA 15.3 was measured using the commercially available CIS
ELSA kit (CIS, High Wycombe, UK).
Biochemical assessment of response to therapy was assess-
ed in the same manner as for all serum markers studied in
our unit (Williams et al., 1990; Robertson et al., 1990, 1992;
Dixon et al., 1993) i.e., any change in marker whilst the
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patient received therapy was related to the pre-treatment
baseline value of the marker and the inter-assay coefficient
(CV) of the marker (<10% for each marker). A cut-off for
each marker of the mean ± 2 s.d. of the normal control
group was calculated. Patients who never showed an eleva-
tion of the marker above this level were regarded as bio-
chemically unassessable for that particular marker. Patients
who started with an initially elevated value which fell to
below the cut-off level or patients with an initial value above
the cut-off level which subsequently decreased by more than
the inter-assay CV (10%) for that marker were regarded as
showing a falling marker level indicative of biochemical res-
ponse and were assigned a score of -2. Patients with an
initial pre-treatment value below the cut-off level which sub-
sequently rose above the cut-off level or patients with an
initial value above the cut-off level which subsequently in-
creased above the inter-assay CV (10%) for that particular
marker were regarded as showing an increased marker level
indicative of biochemical progression and were assigned a
score of +2. Patients whose levels started above and remain-
ed above the cut-off but which moved by less than the
interassay CV (10%) were regarded as biochemically stable
and scored + 1. The CA 15.3 cut off used was 33 U ml-' as
reported previously; 33 U ml-' was chosen as the 'normal'
cut-off value for EMCA i.e., the mean ± 2 s.d. (17+8) of a
normal control group (75 women with no evidence of breast
disease on clinical examination and mammography or another
malignancy) whose range was 3.6-39.6 U ml-'. Changes in
the two markers at 2, 4 and 6 months were compared with
the UICC assessed response at 6 months. The results are
shown in Tables I and II.
Results
EMCA assay precision
Intra-assay coefficients of variation (CV) were calculated for
three samples with EMCA concentrations of 25 U ml-', 75 U
ml-' and 150 U ml-' from the results of 20 pairs of wells in
a single assay; CVs were 5.9, 7.8 and 4.8% respectively.
Inter-assay CVs were calculated for each of three samples
from the results of pairs of wells in 20 different runs and
were 9, 7.9 and 6.2%. Forty zero calibrators (non-specific
binding) wells were processed in a single run along with a set
of non-zero calibrators and controls. Mean and standard
deviation were calculated for the mOD/min of the 40 zero
Table I Pre-treatment EMCA vs 6/12 UICC response
(i) vs 2 months in 77 assessable (>33 Uml-') patients; n = 54
EMCA Biochemical Index Score




XI=24.94; 1 d.f.: P<0.001 (Combining response and static
disease). Sensitivity = 80%; Specificity = 91%; Selectivity =
70%
(ii) vs 4 months in 65 assessable patients; n = 74
EMCA Biochemical Index Score




X2 = 29.06; P<0.001 (Combining response and static disease).
Sensitivity = 91%; Specificity = 92%; Selectivity = 72%
(iii) vs 6 months in 55 assessable patients; n = 1
EMCA Biochemical Index Score




X2 = 20.53; P< 0.001 (Combining response and static disease).
Sensitivity = 86%; Specificity = 89%; Selectivity = 75%
Table II Pre-treatment CA 15.3 vs 6/12 UICC response
(i) vs 2 months in 77 assessable (>33 Uml-') patients; n = 69
CA 15.3 Biochemical Index Score




X=42.59; 1 d.f.: P< 0.001 (Combining response and static
disease). Sensitivity = 85%; Specificity = 91%; Selectivity =
89%
(ii) vs 4 months in 65 assessable patients; n = 57
CA 15.3 Biochemical Index Score




X= 45.60; P< 0.000 (Combining response and static disease).
Sensitivity = 96%; Specificity = 96%; Selectivity = 88%
(iii) vs 6 months in 55 assessable patients; n =69
CA 15.3 Biochemical Index Score




X2= 37.97; P<0.001 (Combining response and static disease).
Sensitivity = 92%; Specificity = 100%; Selectivity = 89%
calibrator wells. The apparent EMCA concentration was
determined at increasing standard deviations from the mean;
sensitivity approximates to 2.3 U ml-' (Table III). In order
to examine parallelism within the assay, three patient samples
were assayed both undiluted and diluted with a zero cali-
brator; observed and expected values are presented (Table
IV).
CA 15.3 assay precision
Intra-assay variation was estimated with sera containing low
(mean 7.8 U ml-'), medium (mean 30 U ml-') and high
values (mean 723 U ml-') of CA 15.3; CVs were 6.9, 5.5 and
4% respectively. The inter-assay CV estimated using the
quality control standard of 30 U ml-' supplied in the manu-
facturer's kit and a serum sample taken from the start of the
study with a moderately high value (782 U ml-) were 9.2
and 7.4% respectively. Examination of the CA 15.3 standard
curve suggested that the assay was not performing well from
Table III Sensitivity of EMCA assay
Mean±s.d. of40
nonspecific binding Apparent Approximate
wells Mean plus concentration Sensitivity
1 s.d. 2.1
3.2±0.3 2 s.d. 2.3 2.3 Uml-'
mOD min-' 3 s.d. 2.4
4 s.d. 2.6
Table IV Parallelism of the EMCA assay
Sample Dilution Observed Uml-' Expected Uml-' %O/E
8 in 8 138 - -
1 4 in 8 69 69 100
2 in 8 34 35 97
lin8 17 17 100
8 in 8 82
2 4 in 8 39 41 95
2 in 8 19 21 91
1 in 8 9 10 90
8 in 8 67
3 4 in 8 34 34 100
2in 8 18 17 100
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Figure 1 Comparison of CA 15.3 concentrations in 'near' (pre-
diluted) and sera diluted x 10.
150 U ml onwards; the curve was flattening off. A com-
parison was then undertaken of values from 25 patients with
prediluted serum samples >140 U ml' and those obtained
after performing a further dilution (x 10) step (Figure 1).
Despite the commercial kit having an upper standard of
240 U ml-' the assay is not linear at concentrations
>140 U ml-; correlation coefficient 0.7. For the purpose of
this study subsequent samples were diluted where possible to
ensure that there concentration at assay was within this
range; linearity was observed at dilutions of 1, 0.8, 0.6, 0.4,
0.2 and 0 with concentrations >140 U ml-' (data not
shown).
Markers in serum
An excellent correlation was observed between changes in
pre-treatment EMCA levels and serum measurements per-
formed at 2, 4 and 6 months and the UICC assessment of
response at 6 months; sensitivity 80%; specificity 91%;
positive predictive value 84% and negative predictive value
89% at 2 months. The selectivity of the EMCA assay for this
cohort of patients with systemic disease was acceptable at
70%. The corresponding values obtained at 4 month assess-
ment were 91%, 92%, 91% and 92% respectively with a
selectivity of 72%. The corresponding correlation of CA 15.3
against response for the same sub-set of patients is outlined
in Table II. Apart from the slightly reduced selectivity of the
EMCA assay the two assays are comparable in terms of their
performance. Whilst four patients remained unassessable by
both EMCA and CA 15.3 throughout the study period, four
of the eight patients who were unassessable by CA 15.3 were
assessable by serial changes in their EMCA levels.
Discussion
Several studies have already been performed using the com-
mercially available CA 15.3 immunoassay for breast cancer
(Hayes et al., 1986; Kerin et al., 1989; Pons-Anicet et al.,
1987; Tondini et al., 1988) confirming CA 15.3 to be a
powerful marker of therapeutic response to endocrine
(Robertson et al., 1990, 1992) and cytotoxic chemotherapy
(Dixon et al., 1993). This assay utilises two monoclonal
antibodies namely 115D8, produced by immunisation against
milk fat globule membranes and DF3 prepared against breast
carcinoma subcellular membranes. These two antibodies
react with the same class of PEM antibody as the EMCA
antibody. Comparative studies with 115D8 however, have
shown that the epitopes defined by this antigen are separate
and distinct from those defined by EMCA, the two assays
measuring epithelial antigens by detection of different deter-
minants (Price et al., 1990).
In summary, this preliminary study has shown that serum
epithelial mucin core antigen (EMCA) appears to reflect
tumour bulk and can be used to accurately monitor systemic
therapy in patients with advanced breast cancer. Apart from
a slight reduction in patient selectivity, EMCA produces
comparable results to the more established CA 15.3. EMCA
is potentially a very important marker in that the assay is
much easier to perform than the CA 15.3 ELSA in only
having two half hour incubations. The ELISA format also
avoids the potential dangers associated with immunoradio-
metric assays. With the EMCA reagents having a long shelf-
life and a variably sized solid phase component, the assay is
particularly suitable for rapid turnover of individual patient
assays at no added cost. The assay also appears to be more
robust than the CA 15.3 kit in that linearity is observed over
the whole analyte range.
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